Canada invests in accelerating stem cell-based therapies for T1D
To wrap up Diabetes Awareness Month, JDRF Canada and the Government of Canada announced an investment in two Canadian research teams that will accelerate the development of stem cell-based therapies for the treatment of type 1 diabetes (T1D).
The research teams are led by Dr. Francis Lynn at the BC Children’s Hospital Research Institute and the University of British Columbia and Dr. Cristina Nostro at the University Health Network and the University of Toronto. The teams will build on Canada’s demonstrated research excellence and leadership in clinical islet transplantation, stem cell biology, diabetes, immunology and genetic engineering to accelerate stem cell-based therapies for T1D. They will work in collaboration with other Canadian researchers to tackle some of the biggest scientific challenges that impede our progress in this area and move us closer to a future where people with T1D will no longer rely on insulin therapy.
This funding is provided through the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), and JDRF Canada, as part of the CIHR-JDRF Partnership to Defeat Diabetes, and CIHR’s initiative 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes.
These Canadian research teams, together with patients and representatives from CIHR and JDRF Canada are working together on these new projects to find new ways to help those that live with T1D.
Read the full news release: